rxstat › Shortages › Insulin Glargine

Insulin Glargine (Lantus, Toujeo Solostar) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Nov 3, 2026

Also sold as: Lantus, Toujeo Solostar, Toujeo Doublestar, Basaglar

Some Insulin Glargine products are in shortage in Canada (2 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jan 15, 2027.

A long-acting insulin used to control blood sugar in diabetes.

Products affected
2 / 6
In shortage since
Aug 31, 2026
Est. full return
Jan 15, 2027
Reports on file
25
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Book a pharmacist appointment
Need your prescription switched?
If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.
See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Active shortage
TOUJEO DOUBLESTAR
300UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02493373 · since Oct 30, 2026, est. end Jan 15, 2027
Active shortage
TOUJEO SOLOSTAR
300UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02441829 · since Aug 31, 2026, no end estimate
Resolved
TOUJEO SOLOSTAR
300UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02441829 · ended Jul 30, 2026
Resolved
TOUJEO SOLOSTAR
300UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02441829 · ended Jul 30, 2026
Resolved
LANTUS
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02251930 · ended Jul 4, 2025
Resolved
LANTUS
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02251930 · ended Feb 22, 2024 · MANUFACTURING DELAY
Resolved
LANTUS
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02294338 · ended Feb 12, 2024 · MANUFACTURING DELAY
Resolved
LANTUS
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02251930 · ended Mar 24, 2023
Resolved
TOUJEO SOLOSTAR
300UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02441829 · ended Mar 7, 2023
Resolved
LANTUS
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02251930 · ended Feb 7, 2023
Resolved
TOUJEO SOLOSTAR
300UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02441829 · ended Jan 18, 2023
Resolved
LANTUS
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02294338 · ended Jan 11, 2023

Showing 12 of 25 reports. All reports are on file with Health Canada.

What's happening

Insulin Glargine is currently affected by 2 active shortage reports filed with Health Canada by SANOFI-AVENTIS CANADA INC.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Insulin Glargine is classified under “INSULINS AND ANALOGUES” (ATC A10AE).

Recent changes

Common questions

What is Insulin Glargine used for?

A long-acting insulin used to control blood sugar in diabetes.

When will Insulin Glargine be back in stock in Canada?

The latest manufacturer estimate is Jan 15, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Insulin Glargine in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (insulins and analogues)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Insulin (Myxredlin) No current shortage Insulin Icodec (Awiqli) No current shortage Insulin Injection Human Biosynthetic (Novolin Ge Toronto Penfill) No current shortage Insulin Aspart (Fiasp) Partial shortage 2 of 8 reported products affected Insulin Glulisine (Apidra) Partial shortage 1 of 3 reported products affected Insulin Lispro (Admelog) Partial shortage 1 of 5 reported products affected

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.